Medical Boards and CEOs
The Review of Corporate Finance Studies · 29.06.2026
DOI: 10.1093/rcfs/cfag008 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Review of Corporate Finance Studies, online erschienen am 29.06.2026. Verfasst von Dunhong Jin und 3 weiteren Autor:innen. Die Arbeit nennt 46 Literaturangaben.
Abstract (Originalsprache)
Approximately 37% of Chinese listed firms possess medical expertise, as indicated by the presence of board members and senior executives with a medical degree or experience in the medical industry. Using the COVID-19 outbreak in China as a natural experiment, we find that the stock returns of firms with medical expertise, excluding those within the healthcare and pharmaceutical industries, are significantly higher than those of firms without such expertise. The positive impact is more pronounced when the CEO or Chairman has medical expertise and when the firm is not state-owned. Overall, this study underscores the importance of diversified executive human capital on firm performance by disentangling the effects of macroeconomic shocks.
Zitieren
APA
Jin, D., Lu, F., Li, S., & Yan, C. (2026). Medical Boards and CEOs. The Review of Corporate Finance Studies. https://doi.org/10.1093/rcfs/cfag008
Vancouver
Jin D, Lu F, Li S, Yan C. Medical Boards and CEOs. The Review of Corporate Finance Studies. 2026. doi:10.1093/rcfs/cfag008
BibTeX
@article{Jin2026,
author = {Jin, Dunhong and Lu, Fangzhou and Li, Sixuan and Yan, Chao},
title = {Medical Boards and CEOs},
journal = {The Review of Corporate Finance Studies},
year = {2026},
doi = {10.1093/rcfs/cfag008}
}
EUVIMED